The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies
- Conditions
- Advanced Malignancies
- First Posted Date
- 2007-05-02
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT00468260
An Extension to Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2007-04-30
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT00467545
- Locations
- π°π·
Novartis Investigative Site , (405-760), In Cheon, Korea, Republic of
π°π·Novartis Investigative Site , (420-717), Gyeonggi-Do, Korea, Republic of
π°π·Novartis Investigative Site (705-035), Daegu, Korea, Republic of
Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT00466466
- Locations
- π«π·
Novartis Investigative Site, Paris, France
πΊπΈDana Faber Cancer Institute, Boston, Massachusetts, United States
πΊπΈHighlands Oncology Group, Fayetteville, Arkansas, United States
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 108
- Registration Number
- NCT00466063
- Locations
- πΊπΈ
East Carolina University, Greenville, North Carolina, United States
πΊπΈChildren's Hospital of Orange County, Orange, California, United States
πΊπΈChildren's Hospital Oakland, Oakland, California, United States
Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients
- Conditions
- De Novo Renal Transplantation
- First Posted Date
- 2007-04-23
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT00464399
- Locations
- π³π΄
Novartis Investigative Site,, Oslo, Norway
A Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With Hypertension
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT00457626
- Locations
- πΉπ·
Novartis Investigative Site, Izmir, Turkey
Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 248
- Registration Number
- NCT00456833
- Locations
- π·πΊ
Novartis Investigative Site, Moscow, Russian Federation
Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 69
- Registration Number
- NCT00457119
- Locations
- π©πͺ
Novartis Investigative Site, Heidelberg, Germany
πΊπΈU of TX Southwestern Medical Center - SimmonsCompCancerCtr Clinical Research Office, Dallas, Texas, United States
πΊπΈMD Anderson Cancer Center/University of Texas Thoractic Head/Neck Med. Onc., Houston, Texas, United States
Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma
- First Posted Date
- 2007-03-29
- Last Posted Date
- 2011-08-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT00454051
- Locations
- π«π·
Novartis Investigator site, Rueil-Malmaison, France
Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 29
- Registration Number
- NCT00451035
- Locations
- π©πͺ
Novartis Investigative Site, Munich, Germany